A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of ...

Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

AstraZeneca PLC has a one year low of $62.75 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.

Q4 2024 Earnings Call Transcript March 31, 2025 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.03, ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful ...